BiotechTube

Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mg

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obstructive Sleep Apnea

Conditions

Obstructive Sleep Apnea, Healthy Subjects

Trial Timeline

Feb 21, 2018 โ†’ Aug 3, 2018

NCT ID
NCT03471871

About Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mg

Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mg is a phase 1 stage product being developed by Eisai for Obstructive Sleep Apnea. The current trial status is completed. This product is registered under clinical trial identifier NCT03471871. Target conditions include Obstructive Sleep Apnea, Healthy Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03471871Phase 1Completed

Competing Products

20 competing products in Obstructive Sleep Apnea

See all competitors
ProductCompanyStageHype Score
Daridorexant + PlaceboIdorsiaPhase 1
28
Mavacamten + PlaceboLianBioPhase 3
69
CT-G20 + PlaceboCelltrionPhase 1
33
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
lysozyme 90 mg + PlaceboEisaiApproved
85
Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mgEisaiPhase 1
33
Eloralintide + PlaceboEli LillyPhase 3
77
Tirzepatide + PlaceboEli LillyPhase 3
77
Arformoterol tartrate inhalation solution + Arformoterol 25 ลณg BID + Formoterol 12 ลณg BID + PlaceboSumitomo PharmaPhase 3
77
arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + Salmeterol + PlaceboSumitomo PharmaPhase 3
77
arformoterol + salmeterolSumitomo PharmaPre-clinical
23
Eszopiclone + PlaceboSumitomo PharmaPhase 2
52
Arformoterol + PlaceboSumitomo PharmaPhase 3
77
Eszopiclone + Placebo controlSumitomo PharmaApproved
85
Eszopiclone + PlaceboSumitomo PharmaPhase 1
33
Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
85
Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
85
Lunesta + Placebo controlSumitomo PharmaApproved
85
Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
85
Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
85

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85